Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Featured post

Aligning Clinical Trial Design with Investment Priorities

When working with investors, it’s critical that drug and device developers consider how their clinical trial design aligns with investment priorities. Natalia Muehlemann and Ari Brettman (Blackstone Life Sciences) discuss what investors look for when evaluating clinical development programs, and the value of simulation-guided design in informing decisions and facilitating communication with investors.

Read full article

Perspectives on Enquiry and Evidence

June 9, 2023

Maximizing Study Momentum: A Case Study in Accelerated DMC Safety Report Creation through IDMC Solutions

In the ever-evolving landscape of clinical development, the need for robust evaluation of interim clinical data through...

Read article

March 18, 2022

The Fundamentals of Real World Evidence in Oncology Drug Development

Real world evidence (RWE) provides a large and growing source of insights into drug uptake and safety. It is...

Read article

October 27, 2021

Leveraging Staged Investment Strategy for Funding Novel Therapies

A staged investment strategy aligns R&D decisions and financial planning with the interim looks of a clinical trial. If...

Read article

October 20, 2021

Strategic Clinical Trial Design Unlocks Innovative Opportunity

For health innovators, trial selection is a key success factor as there are no second chances. But how do you find the...

Read article

August 18, 2021

What does reducing the risk of a faulty conclusion mean: Case study

During the design of a clinical trial, many biotechs want to substantially reduce the risk of a good new therapy being...

Read article

July 28, 2021

Lessons Learned from Leveraging Computing Power for Clinical Strategy

“We found an optimal design in hours that might have taken months to find using standard methods,” reflected Fabien...

Read article

July 22, 2021

The Risk of Under-exploring Trial Design Options: A New Case Study

Earlier this year, Cytel founder Cyrus Mehta observed that clinical trial design is often treated like an art rather...

Read article

May 17, 2017

Case Study: From Trial Design to CDISC Submission

This new case study shares how Cytel supported a specialist biopharmaceutical company from Phase 2 trial design through...

Read article

March 24, 2017

Case Study: Improving Go/No-go Decision-Making with Custom Software

Robust go/no-go (GNG) decision-making is essential for effectively managing risk across a clinical portfolio. In early...

Read article

November 18, 2016

Case Study: Dose-response modeling informs Phase 2 ulcerative colitis study design

Challenge Our client had the following key questions which they wanted our pharmacometrics group to address for an...

Read article

October 22, 2015

Cytel Case Study Series III: Dose Finding & Dose Response Modeling in Pediatric Asthma

Read article

September 15, 2015

Cytel Case Study Series II: Adaptive Bayesian Design with Informative Prior

Read article

September 4, 2015

Using Simulation for Accelerated Early Phase Drug Development

Our Client's Challenge: Can knowledge of the relationship between biomarkers and clinical endpoints help us to optimize...

Read article

January 22, 2015

Adaptive Clinical Trial Strategies for the Limited Early Phase Budget

The Journal of the American Medical Association recently published an article entitled ‘The Anatomy of Medical...

Read article